Early add-on use of belimumab as induction therapy for patients with childhood-onset systemic lupus erythematosus

Lupus. 2024 Apr;33(5):543-544. doi: 10.1177/09612033241238867. Epub 2024 Mar 8.

Authors

Shun Hashimoto¹, Masashi Fujita¹, Tomomi Aizawa^{1

2}, Shojiro Watanabe^{1

3}, Koji Tsugawa¹, Hiroshi Tanaka^{1

4}

Affiliations

¹ Department of Pediatrics, Hirosaki University Hospital, Hirosaki, Japan.
² Niji-iro Children's Clinic, Hirosaki, Japan.
³ Department of Pediatrics, Ehime University Graduate School of Medicine, Toon City, Japan.
⁴ Department of School Health Science, Hirosaki University Faculty of Education, Hirosaki, Japan.

PMID: 38456833
DOI: 10.1177/09612033241238867

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Child
Humans
Immunosuppressive Agents / therapeutic use
Induction Chemotherapy
Lupus Erythematosus, Systemic* / chemically induced
Lupus Erythematosus, Systemic* / drug therapy
Treatment Outcome

Substances

belimumab
Antibodies, Monoclonal, Humanized
Immunosuppressive Agents